News Connection
06/28/2010
The FDA approved alglucosidase alfa (Lumizyme) for patients ≥8 years of age with late-onset, noninfantile Pompe disease, a rare genetic disorder. Alglucosidase alfa, marketed by Genzyme Corporation, is believed to work by replacing the...
The FDA approved alglucosidase alfa (Lumizyme) for patients ≥8 years of age with late-onset, noninfantile Pompe disease, a rare genetic disorder. Alglucosidase alfa, marketed by Genzyme Corporation, is believed to work by replacing the...
The FDA approved alglucosidase...
06/28/2010
First Report Managed Care